E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Low anterior resection syndrome |
Lav anterior resektionssyndrom |
|
E.1.1.1 | Medical condition in easily understood language |
Late effects of rectal surgergy |
Senfølger efter tarmkirurgi |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10080023 |
E.1.2 | Term | Low anterior resection syndrome |
E.1.2 | System Organ Class | 10022117 - Injury, poisoning and procedural complications |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to investigate whether treatment with melatonin has an alleviating effect on LARS symptoms. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective of the study is to investigate how treatment with melatonin affects movements, other patient reported symptoms, quality of life, depression, anxiety, sleep disturbances, motilin levels, and microscopic changes in rectal mucosa. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients should have major LARS (LARS score >29) 2. Patients should have undergone bowel continuity restoring surgery between the last 3 to 24 months 3. Participants should be 18 years or older. 4. Participants must sign an informed consent form
|
|
E.4 | Principal exclusion criteria |
1. Known allergic reaction to melatonin 2. Dementia as determined by mini mental state examination score (MMSE) < 24 3. Participation in another pharmacological intervention trial at the point of inclusion 4. Completed any adjuvant oncological treatment within the last three months 5. Ongoing oncological treatment 6. Rotor or Dubin-Johnson syndrome, epilepsy, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Parkinson’s disease, spinal cord injury, and multiple sclerosis 7. Severe liver disease defined as transaminases above 3 times the normal levels, and severe kidney disease defined as eGFR below 40 ml/min 8. Daily ongoing hypnotic treatment 9. Pre-existing medical sleep disorder diagnosed before the diagnosis of rectal cancer (i.e sleep apnea, restless legs, narcolepsy.) 10. Work involving nightshifts 11. Daily alcohol consumption above 5 units of alcohol (1 unit = 12 g alcohol) 12. Predictable poor compliance (due to pre-existing psychiatric disease, dementia or not able to read or speak sufficient Danish) 13. Pregnant or breastfeeding 14. Severe, life-threatening medical condition, that implies that the patient cannot participate in the study course. (e.g. metastatic disease, local recurrence, stroke, AMI) 15. Females not in menopause (defined as no menstruation during the last 12 months) should not be pregnant. Furthermore, reproductive females should use a secure birth control (intrauterine devices, hormonal contraceptives including – oral pills, patches, vaginal rings and injections) during the entire period of the trial |
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After 4 weeks of treatment |
|
E.5.2 | Secondary end point(s) |
• Daily registration of bowel function • Quality of life measured by EORTC Quality of Life Questionnaire (QLQ-C30 & QLQ-CR29) • Measure Yourself Medical Outcome Profile (MYMOP) • Anxiety measured by Hospital Anxiety and Depression Scale (HADS-A) • Depression measured by Hospital Anxiety and Depression Scale (HADS-D) • Sleep and circadian outcomes measured by actigraphy. • Insomnia severity measured by Insomnia Severity Index (ISI) • Sleep diary • Safety, adverse events, and reactions and compliance by a standardized interview • Blood tests measuring melatonin and difference in gene expression by nanoString • Pathological assessment of the rectal mucosa • Differences in gene expression of the rectal mucosa by NanoString • Assessment of levels of motilin and motilin receptors |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
During the 4 weeks of treatment: • Daily registration of bowel function, actigraphy, and sleep diary
After 4 weeks of treatment • All other end-points |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 0 |